Dermatology

According to a systematic review and meta-analysis of 8776 unique patients, 52.69% achieved repigmentation of >90%.

Two studies demonstrated that the IL-17A and IL-17F inhibitor can lead to superior levels of skin of clearance in adult patients compared with ustekinumab or placebo. .

Phase 3 data showed that Galderma’s Restylane Defyne led to a significant improvement in chin projection for up to 1 year in 74% of patients.

The device was well-tolerated among patients in clinical trials.

Todd Schlesinger, MD, talks new therapies on the horizon and those that have already proven efficacious.

The epicutaneous immunotherapy for peanut allergy is continuing discussions with the FDA. What is its potential in allergic care?